Immunocore's (IMCR) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Immunocore (NASDAQ:IMCR - Free Report) in a research report released on Wednesday morning,Benzinga reports. They currently have a $100.00 target price on the stock.

A number of other analysts have also recently issued reports on IMCR. Morgan Stanley reissued an "equal weight" rating and issued a $35.00 price objective on shares of Immunocore in a research note on Friday, March 7th. Needham & Company LLC reiterated a "buy" rating and set a $71.00 target price on shares of Immunocore in a research report on Thursday, February 27th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, Immunocore presently has an average rating of "Moderate Buy" and an average target price of $65.64.

Immunocore Stock Performance

Shares of IMCR stock traded up $0.53 during trading hours on Wednesday, reaching $28.80. 345,561 shares of the company traded hands, compared to its average volume of 432,123. The firm has a 50-day moving average price of $30.08 and a 200 day moving average price of $31.31. The company has a market cap of $1.44 billion, a P/E ratio of -30.32 and a beta of 0.79. Immunocore has a 12-month low of $27.19 and a 12-month high of $66.00. The company has a debt-to-equity ratio of 1.03, a current ratio of 3.78 and a quick ratio of 3.76.

Remove Ads

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Principal Financial Group Inc. grew its stake in shares of Immunocore by 25.0% in the third quarter. Principal Financial Group Inc. now owns 546,318 shares of the company's stock worth $17,007,000 after acquiring an additional 109,206 shares in the last quarter. Assetmark Inc. grew its stake in Immunocore by 6.5% during the 3rd quarter. Assetmark Inc. now owns 30,555 shares of the company's stock worth $951,000 after purchasing an additional 1,878 shares in the last quarter. Crossmark Global Holdings Inc. purchased a new stake in Immunocore during the 3rd quarter worth about $866,000. GSA Capital Partners LLP purchased a new position in shares of Immunocore in the 3rd quarter valued at about $406,000. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its position in shares of Immunocore by 7.5% during the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 427,152 shares of the company's stock worth $13,297,000 after buying an additional 29,689 shares in the last quarter. Hedge funds and other institutional investors own 84.50% of the company's stock.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.